Market revenue in 2024 | USD 574.2 million |
Market revenue in 2030 | USD 921.0 million |
Growth rate | 8.2% (CAGR from 2024 to 2030) |
Largest segment | Defibrillators |
Fastest growing segment | Defibrillators |
Historical data | 2018 - 2023 |
Base year | 2024 |
Forecast period | 2025 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Pacemakers, Defibrillators, Cardiac Resynchronization Therapy (CRT) |
Key market players worldwide | Stryker Corp, BIOTRONIK, SCHILLER, Medtronic PLC, Abbott Laboratories, Koninklijke Philips NV, ZOLL Medical Corporation, Boston Scientific Corp, LivaNova PLC, Progetti Medical |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to cardiac rhythm management devices market will help companies and investors design strategic landscapes.
Defibrillators was the largest segment with a revenue share of 51.31% in 2024. Horizon Databook has segmented the India cardiac rhythm management devices market based on pacemakers, defibrillators, cardiac resynchronization therapy (crt) covering the revenue growth of each sub-segment from 2018 to 2030.
Cardiovascular diseases, including cardiac arrhythmias, are a leading cause of morbidity and mortality in India. Factors such as urbanization, unhealthy dietary habits, and the rising prevalence of risk factors like hypertension & diabetes contribute to the growing burden of CVDs. As a result, there is a high demand for CRM devices to diagnose and treat cardiac arrhythmias.
According to the National Crime Records Bureau, there is a notable 12.5% rise in the number of fatalities attributed to heart attacks in 2022 compared to the preceding year. The report highlights that 32,457 people succumbed to heart attacks in 2022, marking a significant increase from the 28,413 deaths reported in 2021.
Patients who have experienced a heart attack and are at high risk of recurrent arrhythmias or sudden cardiac death require secondary prevention strategies, which often involve the implantation of EP devices. This includes individuals with reduced left ventricular function, significant coronary artery disease, or a history of arrhythmias.
Horizon Databook provides a detailed overview of country-level data and insights on the India cardiac rhythm management devices market, including forecasts for subscribers. This country databook contains high-level insights into India cardiac rhythm management devices market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account